Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (TARS) is a commercial-stage biopharmaceutical leader pioneering novel therapies for underserved ophthalmic conditions. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical developments, and strategic initiatives driving innovation in eye care therapeutics.
Access authoritative updates on XDEMVY commercialization progress, pipeline advancements for TP-04 and TP-05, and financial performance metrics. Our curated collection includes earnings reports, FDA correspondence, peer-reviewed research publications, and partnership announcements – all essential for understanding TARS's market position.
Key updates cover:
• Prescription drug approval statuses
• Clinical trial phase completions
• Commercialization partnerships
• Quarterly financial disclosures
Bookmark this page for unfiltered access to Tarsus Pharmaceuticals' official communications. For comprehensive analysis of how these developments impact the biopharmaceutical landscape, consult your financial advisor and review SEC filings.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that Bobak Azamian, M.D., Ph.D., CEO and Chairman, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference. The event aims to revolutionize treatment for patients, starting with eye care. The webcast and presentation details are available on the Tarsus website.
Tarsus Pharmaceuticals, Inc. reported a successful first quarter of 2024, with $24.7 million in net product sales of XDEMVY, an 89% increase over the previous quarter. The company delivered approximately 26,000 bottles of XDEMVY to patients, expanded its sales force, secured multiple commercial payer contracts, and strengthened its financial position with a public equity offering and financing commitment. Tarsus remains on-track for broad commercial coverage by the end of 2024 and Medicare coverage in 2025. The company continues to advance its pipeline and engage with the FDA on new treatments. Despite positive revenue growth, Tarsus saw an increase in net loss due to higher expenses, primarily in research and development as well as selling, general, and administrative costs.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will report its first quarter 2024 financial results on May 8, 2024. The company focuses on unmet needs in eye care. A live webcast will be held to provide the results and a corporate update.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
